Kamada Ltd. (KMDA) 股票分析

公司概述

Kamada Ltd. is a specialized manufacturer and distributor of plasma-derived protein therapeutics designed for specific medical prophylaxis applications. The company operates within the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry, which focuses on producing niche pharmaceuticals rather than mass-market consumer drugs. The firm employs a workforce of 462 individuals to support its operations in developing and selling critical therapies such as KAMRAB/KEDRAB for rabies prevention, CYTOGAM for cytomegalovirus disease prophylaxis in transplant patients, and VARIZIG for post-exposure varicella-zoster virus prophylaxis. With a market capitalization of $492.01M and annual revenue (TTM) of $180.46M, Kamada Ltd. maintains a significant presence in the specialty drug market. These valuation and revenue figures indicate that the company has established a substantial market footprint, positioning it as a mid-sized entity capable of generating consistent cash flows while serving a high-value, low-volume niche within the global healthcare landscape.

财务健康

Kamada Ltd. reported total revenue of $180.46M over the trailing twelve months, generating a net income of $20.20M and an EBITDA of $39.51M. The gap between the revenue figure and the net income reveals a cost structure where operating expenses, including cost of goods sold and administrative costs, consume approximately 88.8% of total revenue, leaving the remaining portion as profit. The company generated free cash flow of $7.59M, which demonstrates positive operational efficiency and provides the financial flexibility to fund research, development, or return capital to shareholders without relying heavily on external financing. Profitability is further detailed by three key margin metrics: a gross margin of 42.3%, an operating margin of 7.9%, and a profit margin of 11.2%. The gross margin indicates the pricing power and production efficiency in sourcing plasma-derived proteins, while the operating and profit margins reflect the company's ability to control overhead and deliver earnings to shareholders. On the balance sheet, the company holds $75.47M in cash against $11.56M in debt, resulting in a debt-to-equity ratio of 4.30. This leverage metric suggests a capital structure that utilizes debt to finance operations, though the substantial cash reserve provides a robust buffer against interest obligations. Liquidity is exceptionally strong, evidenced by a current ratio of 4.07, which indicates the company possesses more than four times the current assets necessary to cover its short-term liabilities. Return metrics show a Return on Equity of 7.6% and a Return on Assets of 4.4%, revealing that management effectiveness in generating returns on shareholder capital is moderate relative to the asset base employed.

估值评估

The stock carries a trailing P/E ratio of 24.31 and a forward P/E of 14.34, implying that the market expects earnings to grow significantly in the future to justify the lower forward multiple. The price-to-book ratio stands at 1.82, indicating that the market values the company at a premium of 82% over its net asset book value, reflecting intangible assets like intellectual property and brand equity. Alternative valuation metrics include a price-to-sales ratio of 2.73 and an EV/EBITDA of 10.81, which suggest the company is trading at a premium relative to its sales and earnings power compared to traditional large-cap pharmaceutical peers. Regarding price momentum, the 52-week trading range spans from a low of $5.54 to a high of $9.35. Without the current specific share price in the provided facts, the analysis focuses on the range boundaries which define the volatility envelope for the stock. The beta value is 0.31, which indicates that the stock price is significantly less volatile than the broader market, moving with only about one-third of the magnitude of market swings. This low beta suggests that Kamada Ltd. functions as a defensive holding that offers stability during periods of general market turbulence, appealing to investors seeking lower correlation with the S&P 500.

Growth & Income

Revenue growth for the trailing twelve months was 14.5% year-over-year, while earnings growth was -14.1% year-over-year. This divergence indicates that earnings are currently growing slower than revenue, implying that the company may be facing rising cost pressures or one-time charges that are compressing net margins despite top-line expansion. The company does not pay a dividend, as indicated by a payout ratio of 0.0%, meaning it retains all earnings rather than distributing them to shareholders. Consequently, the firm reinvests its generated cash flows directly back into the business, likely funding new product pipelines, manufacturing capacity, or strategic acquisitions to drive future organic growth. The overall growth and income profile presents a scenario of expanding sales volume that has not yet translated into proportional earnings growth, supported by a strategy of capital retention rather than dividend distribution. This approach prioritizes long-term expansion over immediate income yield, which is typical for specialty pharmaceutical companies in the growth phase of their product lifecycle.